Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia

PACE - Pacing and Clinical Electrophysiology

Volumn 35, Issue 7, 2012, Pages 794-797

  Hong, Robert A ^a   Rivera, Kahealani K ^a   Jittirat, Arksarapuk ^a   Choi, Joon J ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

calsequestrin 2; catecholaminergic polymorphic ventricular tachycardia; defibrillator induced storming; flecainide; mutation; ryanodine receptor

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALSEQUESTRIN 2; DILTIAZEM; DRONEDARONE; ESMOLOL; FLECAINIDE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CASE REPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; DEFIBRILLATOR; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC SCREENING; HEART ARREST; HEART PACING; HUMAN; MALE; SUBSTITUTION REACTION; SUDDEN DEATH;

EID: 85027934091     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2012.03421.x     Document Type: Article

References (11)

1. Coumel P,. Catecholaminergic polymorphic ventricular tachyarrhythmias in children. Card Electrophysiol Rev 2002; 6: 93-95. (Pubitemid 34213324)
2. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, et al,. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie CPVT. Circulation 2001; 103: 196-200.
3. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A, Lorber A, et al,. Autosomal recessive catecholamine- or exercise-induced polymorphic VT: Clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103: 2822-2827. (Pubitemid 32550071)
4. Rosso R, Kalman J, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, et al,. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in CPVT. Heart Rhythm 2007; 4: 1149-1154. (Pubitemid 47324118)
5. Fagundes A, DE Magalhaes LP, Russo M, Xavier E,. Pharmacological treatment of electrical storm in CPVT. Pacing Clin Electrophysiol 2010; 33: e27-e31.
6. de la Fuente S, Van Langen IM, Postma AV, Bikker H, Meijer A,. A case of CPVT caused by two CASQ2 mutations. Pacing Clin Electrophysiol 2008; 31: 916-919.
7. Wilde A, Bhuiyan A, Crotti L, Facchini M, De Ferrari G, Paul T, Ferrandi C, et al,. Left cardiac sympathetic denervation for CPVT. N Engl J Med 2008; 358: 2024-2029.
8. Robinson M, Park J, Raff G,. Novel palliative therapy for drug-refractory CPVT in a young patient: Cardiac autotransplantation followed by orthotopic transplantation. Heart Rhythm 2007; 4 (5 Suppl.): S101.
9. Watanabe H, Chopra N, Laver D, Hwang H, Davies S, Roach D, Duff H, et al,. Flecainide prevents CPVT in mice and humans. Nat Med 2009; 15: 380-383.
10. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, et al,. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with CPVT. J Am Coll Cardiol 2011; 57: 2244-2254.
11. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand S, Chopra N, Piston D, et al,. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol 2010; 48: 293-301.